The page outlines the full BNCT treatment process, including patient assessment, boron drug administration, neutron irradiation, and post-treatment care, emphasizing precision and short treatment duration.
Boron neutron capture therapy (BNCT) targets cancer cells at the cellular level while minimizing damage to healthy tissue. The page explains how AB-BNCT achieves high-precision, low-side-effect cancer treatment.
Hehong Technology offers high-performance cyclotrons for PET and radioisotope production. The TR series (TR-FLEX, TR-24, TR-30) features high current and multi-target designs, along with comprehensive solutions for hospitals and nuclear medicine centers.
The study compares three bolus placement methods in BNCT for superficial oral and head and neck cancers, finding that a 1 cm bolus on the skin surface significantly improves tumor dose absorption.
Heron Neutron Medical partners with GE HealthCare to develop AI-driven imaging solutions for accelerator-based boron neutron capture therapy (AB-BNCT). The collaboration focuses on integrating advanced imaging techniques to enhance precision in cancer treatment. Heron Neutron specializes in accelerator-based BNCT systems, while GE HealthCare brings expertise in healthcare technology and AI applications.
National Yang Ming Chiao Tung University (NYCU) and HERON jointly launch a research center focused on boron neutron capture therapy (BNCT) and advanced medical imaging. The groundbreaking ceremony, led by NYCU President Chi-Hung Lin and HERON Chairman Chin-Jung Hsu, formalizes their partnership to develop next-generation medical technologies. The center aims to advance cancer treatment and diagnostic imaging through collaborative innovation.
Heron Neutron Medical Corp. showcases its integrated boron neutron capture therapy (BNCT) solutions at **ASTRO 2026** in Boston. The company highlights advancements in treatment planning and clinical workflows for oncology applications. Visitors can explore innovations designed to improve precision in neutron-based cancer therapies.
Heron Neutron Medical Corp. reports its **B10 L-BPA Injection** shows **promising safety and efficacy** in a **Phase I/II investigator-initiated trial** for **recurrent meningioma**. The proprietary treatment undergoes evaluation in a clinical setting targeting patients with this brain tumor type. Results suggest potential therapeutic benefits without immediate signs of adverse effects.
National Yang Ming Chiao Tung University (NYCU) and **Heron Neutron Medical Corp.** signed a **Memorandum of Understanding (MOU)** in Miaoli to collaborate on developing a **medical technology park** and fostering talent in **Boron Neutron Capture Therapy (BNCT)**. The agreement was witnessed by Miaoli County Magistrate Chung Tung-chin during a ceremony at the Miaoli County Government. The partnership aims to integrate academic research with industry applications in advanced medical technologies.
Heron Neutron Medical Corp. and National Yang Ming Chiao Tung University (NYCU) collaborate to establish the **Bo-Ai Campus Boron Neutron Capture Therapy (BNCT) & Advanced Imaging Research Center**. The partnership formalizes research efforts in precision medicine, combining Heron’s neutron-based therapies with NYCU’s academic expertise. The center aims to advance BNCT—a targeted cancer treatment—and imaging technologies for clinical applications.
Heron Neutron Medical partners with B dot Medical to expand particle therapy solutions in Asia. The collaboration aims to accelerate adoption of their core products across the Pan-Asian market through a signed Memorandum of Understanding (MOU). Both companies specialize in next-generation cancer treatment technologies.
Heron is collaborating with Siemens Healthineers and international partners to expand **AB-BNCT** (antibody-based boron neutron capture therapy) for precision cancer treatment. The initiative aims to accelerate clinical adoption and global accessibility of this targeted therapy. AB-BNCT combines monoclonal antibodies with neutron capture to destroy tumor cells selectively.
Heron Neutron Medical Corp. signs a Letter of Intent with UAE-based **The Node Company** to expand its **AB-BNCT cancer treatment** across Gulf Cooperation Council (GCC) markets. The agreement aims to broaden access to Heron’s neutron-based therapy in the region. Both companies collaborate to accelerate deployment of the treatment in healthcare facilities.
HERON partners with Taipei Veterans General Hospital (TVGH) to develop **AB-BNCT**, a boron neutron capture therapy, for **first-line treatment of head and neck cancer**. The collaboration aims to accelerate clinical research and evaluate its potential as an early-stage therapy. HERON specializes in targeted radiation treatments, while TVGH provides clinical expertise and patient access for trials.
Heron Neutron Medical Corp. partners with NUS Medicine to advance research on the radiotracer **18F-FBPA**, a potential diagnostic tool for neurodegenerative diseases. The collaboration aims to explore clinical applications and expand global access to precision imaging solutions. Both institutions combine expertise in radiopharmaceuticals and neurology to accelerate development.